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Advanced glycation end products inhibit de novo protein syn- Diabetic nephropathy is a leading cause of end-stage
thesis and induce TGF- overexpression in proximal tubular cells. renal disease, and accounts for disabilities and the high
Background. We have shown previously that OPB-9195, a
mortality rates in patients [1, 2]. Diabetic nephropathynovel inhibitor of advanced glycation end products (AGE),
is characterized by functional and structural changes insignificantly prevented renal tubular injury and tubulointersti-
tial fibrosis in spontaneous diabetic rats. However, the molecu- the glomerulus, such as glomerular hyperfiltration, thick-
lar mechanisms underlying this have not been fully elucidated. ening of glomerular basement membranes and an expan-
Methods. Three immunochemically distinct AGE were pre-
sion of extracellular matrix in mesangial areas [3]. How-pared by incubating bovine serum albumin (BSA) with glucose,
ever, it has recently been recognized that changes withinglyceraldehyde, or methylglyoxal. Then, the effects of AGE on
human proximal tubular epithelial cells were examined. The intra- tubulointerstitium are more important than glomerulo-
cellular formation of reactive oxygen species (ROS) was detected pathy in terms of renal prognosis in diabetic nephropathy
using the fluorescent probe CM-H2DCFDA. DNA synthesis was [4–6]. These changes include proximal tubular cell atro-evaluated by thymidine uptake, and de novo protein synthesis
phy and tubulointerstitial fibrosis [7, 8]. Indeed, such tu-was determined by [3H]leucine incorporation. Prostaglandin E2
(PGE2) and transforming growth factor- (TGF-) released into bular changes have been reported to be the dominant le-
media were quantitatively analyzed in an enzyme-linked immuno- sion in about one third of patients with type 2 diabetes [9].sorbent assay. TGF- gene expression was analyzed by quantita-
Reducing sugars, including glucose, fructose and triosestive reverse transcription-polymerase chain reaction (RT-PCR).
Results. When these AGE-BSA were administered to tubular can react non-enzymatically with the amino groups of
cells, each of them increased generation of intracellular ROS. proteins to form reversible Schiff bases, and then Ama-
All of the AGE-BSA, but not non-glycated BSA, were found dori products [10–12]. This early glycation reaction leadsto induce statistically significant decreases in de novo protein
through complex reactions such as rearrangement, dehy-synthesis and PGE2 secretion by tubular cells. Furthermore,
AGE-BSA up-regulated the levels of mRNAs for TGF- in dration and condensation to a broad range of heteroge-
tubular cells. The structural epitope designated glucose-derived neous fluorescent derivatives termed advanced glycation
AGE was found to have the greatest cytopathic effects on end products (AGE) [13, 14]. The formation and accu-tubular cells. These AGE-induced inhibition of protein synthe-
mulation of AGE in various tissues are known to irrevers-sis and PGE2 secretion as well as the up-regulation of TGF-
mRNA were found to be completely prevented by N-acetylcys- ibly progress during normal aging and at an extremely
teine. Furthermore, H2O2 was shown to inhibit protein synthe- accelerated rate in diabetes mellitus. Recent understand-
sis and PGE2 secretion by proximal tubular cells in a dose- ings of this process have confirmed that AGE are impli-dependent manner.
Conclusion. The results suggest that AGE inhibits de novo cated in the development and progression of diabetic
protein synthesis and stimulates TGF- mRNA expression in micro- and macrovascular complications [15–23].
proximal tubular epithelial cells through overgeneration of in- We have shown previously that OPB-9195, a noveltracellular ROS. Thus, AGE are involved in the pathogenesis
inhibitor of AGE, significantly prevented renal tubularof tubular injury in diabetic nephropathy.
injury and tubulointerstitial fibrosis in Otsuka Long-
Evans-Tokushima Fatty rats, a model animal of type 2Key words: glycation, tubular injury, diabetic nephropathy, reactive
oxygen species, end-stage renal disease, prostaglandin E2. diabetes [24, 25]. However, the molecular mechanisms
underlying this action have not been fully elucidated.Received for publication December 3, 2001
Very recently we found that AGE can arise not onlyand in revised form July 23, 2002
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[26]. Therefore, for the present study, we prepared three were carried out in a serum-free assay medium con-
taining 10 g/mL transferrin and GA-1000.immunochemically distinct AGE in vitro by incubating
bovine serum albumin (BSA) with glucose (glu-AGE-
Intracellular ROS
BSA), glyceraldehyde (glycer-AGE-BSA), or methyl-
The intracellular formation of ROS was detected byglyoxal (methyl-AGE-BSA). Then we investigated the
using the fluorescent probe CM-H2DCFDA (Moleculareffects of AGE-BSA on de novo protein synthesis, pros-
Probes Inc., Eugene, OR, USA) as described previouslytaglandin E2 (PGE2) secretion and transforming growth
[27]. Briefly, cells (1  105/96-well plates) were loadedfactor-1 (TGF-1) gene expressions in human proximal
with 10 mol/L CM-H2DCFDA, incubated for 45 min-tubular epithelial cells. We demonstrated that all of these
utes at 37C, and analyzed in an EZS-FL fluorescentdifferent types of AGE cause tubular atrophy and elicit
plate reader (Asahi Techno Glass, Tokyo, Japan) usingischemic and fibrogenic damage to proximal tubular cells
the EZScan-FL for Windows program.through intracellular overgeneration of reactive oxygen
species (ROS). Preparation of polyclonal antibodies against
glu-AGE-BSA
METHODS Antibodies against glu-AGE-BSA were prepared as
Materials described previously [26].
Bovine serum albumin (fraction V), methylglyoxal, Preparation of AGE-containing serum from control
and N-acetylcysteine (NAC) were purchased from Sigma and diabetic patients
(St. Louis, MO, USA). d-glyceraldehyde and trichloro-
Advanced glycation end products containing serumacetic acid were from Nakalai Tesque (Kyoto, Japan).
(molecular weight 10 kD) were prepared from controld-glucose and H2O2 were purchased from Wako Pure
and diabetic patients as described previously [26].Chemical Industries, Ltd. (Osaka, Japan). [3H]Thymi-
dine, [3H]leucine, [-32P]ATP, Hybond-N nylon mem- Measurements of [3H]leucine and
brane and PGE2 enzyme immunoassay system were from [3H]thymidine incorporation
Amersham Pharmacia Biotech (Buckinghamshire, UK). Cells were plated at 1 105 cells/well in 12-well plates.
Reverse transcriptase and T4 polynucleotide kinase were The next day, cells were rested in a serum-free assay
from Takara (Kyoto, Japan). medium for 24 hours, and then treated with or without
AGE proteins in the presence or absence of variousPreparation of AGE-BSA and carboxymethyllysine
concentrations of H2O2 for 72 hours. For the last 16(CML)-BSA
hours of the culture, cells were pulsed with 2 Ci [3H]leu-Advanced glycation end products-BSA were prepared
cine. After cells were washed with ice-cold PBS, they wereas described previously [26]. Briefly, BSA was incubated
fixed with ice-cold 10% (wt/vol) trichloroacetic acid forunder sterile conditions with d-glucose, d-glyceralde-
15 minutes, and the resultant acid-insoluble materials werehyde or methylglyoxal in 0.2 mol/L phosphate buffer at
processed for liquid scintillation counting. [3H]Thymidine
37C for seven days, except for glucose (8-week incuba-
incorporation was determined as described previously
tion). CML-BSA was prepared by incubating BSA with
[28].
glyoxylic acid and sodium cyanoborohydride as described
Measurement of PGE2previously [26]. Then unincorporated sugars were re-
moved by dialysis against phosphate-buffered saline Cells were plated at 1 105 cells/well in 12-well plates.
(PBS). Control non-glycated BSA was incubated in the The next day, cells were rested in a serum-free assay
same conditions except for the absence of reducing sug- medium for 24 hours, and then treated with or without
ars. Preparations were tested for endotoxin using Endo- AGE-BSA in the presence or absence of H2O2 for 48
specy ES-20S system (Seikagaku Co., Tokyo, Japan); no hours. PGE2 released into media was measured with an
endotoxin was detectable. enzyme immunoassay system according to the manufac-
turer’s instructions.Cells
Primers and probesProximal tubular epithelial cells from human kidney
were maintained in REBM medium supplemented with Sequences of the upstream and down stream primers
5% fetal bovine serum (FBS), 0.5g/mL hydrocortisone, and the internal probe for quantitative RT-PCR were
10 ng/mL human epidermal growth factor (EGF), 0.5 5-CAGAAATACAGCAACAATTCCTGG-3, 5-TTG
g/mL epinephrine, 6.5 ng/mL triiodo-l-thyronine, 10 CAGTGTGTTATCCCTGCTGTC-3 and 5-CGATA
g/mL transferrin, 5 g/mL insulin, and GA-1000 ac- CCTCAGCAACCGGCT-3 (nucleotides 1358–1381, 1520–
cording to the supplier’s instructions (Clonetics Corp., 1543, and 1382–1401) for detecting human TGF- mRNA
San Diego, CA, USA). Cells at three to five passages were [29]. The primers and probe used for -actin mRNA detec-
tion were the same as described previously [30].used for the experiments. AGE and H2O2 treatments
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Fig. 1. Effects of advanced glycation end products-bovine serum albumin (AGE-BSA) or diabetic serum on intracellular reactive oxygen species
(ROS) generation in tubular cells. (A) Cells were treated with 100 g/mL of various types of AGE-BSA or non-glycated BSA, and then ROS
were quantitatively analyzed. (B) Dose-effects of glu-AGE on ROS generation. (C ) Cells were treated with 100 g/mL of glu-AGE-BSA or non-
glycated BSA in the presence or absence of 10 g/mL of polyclonal antibody against glu-AGE, and then ROS were analyzed. (D) Cells were
treated with control or diabetic serum in the presence or absence of 10 g/mL of polyclonal antibody against glu-AGE, and then ROS were
analyzed. *P 	 0.01 compared to the value of the control with non-glycated BSA (Student t test). #P 	 0.05 compared to the value with glu-
AGE-BSA alone (Student t test). P 	 0.01 compared to the value with diabetic serum alone (Student t test).
Quantitative RT-PCR signal intensities as functions of the template amounts
and cycle numbers [32]. Signal intensities of hybridizedPoly(A)RNAs were isolated [31] from cells treated
bands were measured by microcomputer-assisted NIHwith or without AGE-proteins for the various time peri-
Image (Version 1.56).ods, and analyzed by reverse transcription-polymerase
chain reaction (RT-PCR) as described previously [32].
Measurement of active TGF- proteinsTen-microliter aliquots of each RT-PCR reaction mix-
Cells were plated at 1 105 cells/well in 12-well plates.ture were electrophoresed on a 1.2% agarose gel, trans-
The next day, cells were rested in a serum-free assayferred to a Hybond-N nylon membrane, and the mem-
medium for 24 hours, and then treated with or withoutbrane was hybridized with the respective 32P-end labeled
AGE-BSA for 24 hours. TGF- released into media wasprobes [32]. The amounts of poly(A)RNA templates
measured with an enzyme immunoassay system (Pro-(30 ng) and cycle numbers (35 cycles) for amplification
mega, Madison, WI, USA) according to the manufactur-were chosen in quantitative ranges, where reactions pro-
ceeded linearly, which had been determined by plotting er’s instructions.
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Fig. 2. Effects of AGE-BSA on [3H]leucine incorporation into tubular
cells. (A) Cells were treated with or without 100 g/mL of various types
of AGE-BSA in the presence or absence of 10 mmol/L of NAC for 72
hours. For the last 16 hours of the culture, cells were pulsed with 2 Ci
[3H]leucine. After cells were washed with ice-cold PBS, [3H]leucine in-
corporation into the cells was assayed. The percentage of [3H]leucine
incorporation is indicated on the ordinate and related to the value with
non-glycated BSA. (B) Cells were treated with 100 g/mL of glu-AGE-
BSA or non-glycated BSA in the presence or absence of 10 g/mL of
polyclonal antibody against glu-AGE, and then leucine incorporation
was measured. *P 	 0.01 compared to the value of the control with
non-glycated BSA (Student t test). #P 	 0.01 compared to the value
with glu-AGE-BSA alone (Student t test).
Statistical analysis To confirm the specificity of glu-AGE effects on tubu-
lar cells, we next investigated whether antibodies againstAll values were presented as means
 SEM. Statistical
glu-AGE-BSA could actually neutralize the glu-AGE-significance was evaluated using the Student t test for
induced increase in ROS generation. As shown in Figurepaired comparison; P 	 0.05 was considered significant.
1C, the antibodies were found to completely block the
glu-AGE-induced ROS generation in tubular cells.
RESULTS
Effects of diabetic serum on intracellular ROS
Effects of AGE-BSA on intracellular ROS production production in proximal tubular epithelial cells
in proximal tubular epithelial cells
Next the question of whether AGE-containing serum
As shown in Figure 1A, various synthetic AGE conju- of diabetic patients could increase ROS generation in tu-
gated to BSA as a carrier protein, but not unmodified bular cells was investigated. As shown in Figure 1D, com-
BSA, significantly increased the intracellular ROS gener- pared with control serum, serum from diabetic patients
ation in human proximal tubular epithelial cells. Further, significantly increased ROS generation in tubular cells.
glu-AGE were found to stimulate ROS production in tu- Antibodies against glu-AGE-BSA significantly prevented
bular cells in a dose-dependent manner (Fig. 1B). Among the diabetic serum-induced increase in ROS generation in
the different types of AGE-proteins, 100 g/mL of glu- tubular cells, suggesting that the immunological epitopes
AGE-BSA caused the most significant effects on tubular of in vitro-prepared glu-AGE-BSA might be involved in
oxidative stress in proximal tubular cells in vivo.cells, increasing ROS production about 1.7-fold.
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Fig. 3. Effects of H2O2 on [3H]leucine incorporation into tubular cells.
Cells were treated with or without various concentrations of H2O2 for Fig. 4. Effects of AGE-BSA on [3H]thymidine incorporation into tubu-
72 hours. For the last 16 hours of the culture, cells were pulsed with 2Ci lar cells. Cells were treated with or without 100 g/mL of various types
[3H]leucine. After cells were washed with ice-cold PBS, [3H]leucine in- of AGE-BSA for 48 hours. For the last 4 hours of the culture, cells
corporation into the cells was assayed. The percentage of [3H]leucine were pulsed with 2 Ci [3H]thymidine. After cells were washed with
incorporation is indicated on the ordinate and related to the value ice-cold PBS, [3H]thymidine incorporation into the cells was assayed.
without additives. *P 	 0.05; **P 	 0.01 compared to the value of the The percentage of [3H]thymidine incorporation is indicated on the ordi-
control without additives (Student t test). nate and related to the value with non-glycated BSA.
Effects of AGE-BSA and H2O2 on [3H]leucine and secretion was reduced to 40% of that of the control when
[3H]thymidine incorporation exposed to glu-AGE-BSA for 48 hours (Fig. 5). Co-treat-
ment with 10 mmol/L NAC completely prevented theIncorporation of [3H]leucine into acid-precipitable pro-
effects of AGE, and further H2O2 significantly inhibitedteins is used as a sensitive index of de novo protein synthe-
PGE2 secretion by tubular cells in a dose-dependent man-sis in cultured cells. Thus, the effects of AGE on [3H]leu-
ner (Fig. 6). These results suggest that intracellular ROScine incorporation into tubular cells were investigated. As
generation could be implicated in suppression of PGE2shown in Figure 2A, various types of AGE-BSA signifi-
secretion by proximal tubular cells.cantly inhibited de novo protein synthesis in tubular cells.
Of note, tubular cells displayed a 70% decrease in leucine
Proximal tubular epithelial cells express mRNA forincorporation when exposed to glu-AGE-BSA for 72
TGF- in response to AGE-BSAhours. Co-treatment with 10 mmol/L NAC was found to
completely prevent the effects of AGE (Fig. 2A). Fur- Poly(A) RNAs were isolated from tubular cells treated
thermore, antibodies against glu-AGE-BSA completely with various types of AGE-proteins for various time
blocked the glu-AGE-induced decrease in leucine incor- periods in the presence or absence of NAC or antibodies
poration in tubular cells (Fig. 2B). against glu-AGE-BSA, and analyzed by a quantitative
To confirm that intracellular ROS generation was in- RT-PCR technique to determine the effects of AGE on
volved in protein synthesis, the effects of H2O2 on [3H]leu- the expression of TGF- genes. As shown in Figure 7, A
cine incorporation into tubular cells were studied. As and B, when the tubular cells were exposed to various
shown in Figure 3, H2O2 inhibited [3H]leucine incorpora- types of AGE-BSA, the levels of TGF- mRNAs were
tion in a dose-dependent manner. None of these AGE- found to be significantly increased; glu-AGE-BSA up-
proteins reduced [3H]thymidine incorporation into tubular
regulated TGF- mRNA levels about fivefold (Fig. 7B).cells, demonstrating that AGE did not affect DNA synthe-
Co-treatment with 10 mmol/L NAC completely preventedsis in this type of cell (Fig. 4). We also confirmed that the
the effects of AGE on TGF- mRNA up-regulation,viable cell numbers of tubular cells were not affected by
suggesting that intracellular ROS generation is involvedthese AGE treatments for two days (data not shown).
in the induction of TGF- genes in proximal tubular
Effects of AGE-BSA and H2O2 on PGE2 secretion by cells (Fig. 7C). Further, as the case in ROS generation,
proximal tubular cells serum of diabetic patients significantly up-regulated
TGF-mRNA levels in tubular cells (Fig. 7D). Antibod-Advanced glycation end products-BSA significantly de-
creased PGE2 secretion by proximal tubular cells; PGE2 ies against glu-AGE were found to inhibit the diabetic
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Fig. 5. Effects of AGE-BSA on prostaglan-
din E2 (PGE2) secretion by tubular cells. Cells
were treated with or without 100 g/mL of
various types of AGE-BSA in the presence
or absence of 10 mmol/L of NAC for 48 hours.
PGE2 released into media was measured with
an enzyme immunoassay system. *P 	 0.01
compared to the value of the control with non-
glycated BSA (Student t test).
DISCUSSION
Our previous study showed that OPB-9195, a novel
inhibitor of AGE, significantly prevented renal tubular
injury and tubulointerstitial fibrosis in spontaneous dia-
betic rats [24, 25]. The present study demonstrates, to
our knowledge for the first time, that various types of
AGE, non-enzymatically glycated protein derivatives
formed at an accelerated rate under diabetes, inhibit
de novo protein synthesis in human proximal tubular
epithelial cells. Since the AGE-BSA did not affect DNA
synthesis and viable cell numbers in these cells, AGE
might be involved in the pathogenesis of tubular atrophy,
one of the representative tubulointerstitial changes in
diabetic nephropathy [7]. We recently showed that the
structural epitope of in vitro-modified AGE-proteins ac-
tually existed in the serum of diabetic patients [33, 34].
Further, we have previously demonstrated that the se-Fig. 6. Effects of H2O2 on PGE2 secretion by tubular cells. Cells were
rum concentrations of glu-AGE were about 30 to 50g/mLtreated with or without various concentrations of H2O2 for 48 hours.
PGE2 released into media was measured with an enzyme immunoassay in diabetics, and its levels were increased two- to three-
system. *P	 0.05 compared to the value of the control without additives fold in diabetic patients with uremia [33, 35]. These ob-(Student t test).
servations showed that the concentration of glu-AGE
used in this experiment was comparable to that of the
serum-induced TGF- mRNA up-regulation, thus sug- in vivo situation in diabetes. Since the serum concentra-
gesting that the immunological epitopes of in vitro-pre- tions of glycer-AGE and methyl-AGE were relatively
pared glu-AGE-BSA might participate in tubular injury low, being 1/5 to 1/3 of that of glu-AGE in diabetes
in diabetes. [34], the immunological epitopes of glu-AGE rather than
To confirm whether AGE actually increased the syn- glycer-AGE or methyl-AGE may participate in tubular
thesis of active TGF- proteins, an enzyme immunoassay injury in diabetes. In support of this observation, the pres-
was performed for active TGF- proteins in a medium of ent study found that antibodies against glu-AGE-BSA
the cells that had been treated with or without 100 g/mL that did not cross-react with glycer-AGE or methyl-
of various types of AGE-BSA for 24 hours. As shown AGE significantly inhibited the diabetic serum-induced
in Figure 8, active TGF- proteins were secreted more ROS generation as well as TGF- up-regulation in tubu-
lar cells. Antibodies against glu-AGE also did not to cross-by cells exposed to AGE than the controls.
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Fig. 7. Expression of transforming growth factor- (TGF-) gene in tubular cells. (A) Time course of TGF- mRNA induction by various types
of AGE-BSA. Cells were treated with or without 100 g/mL of different types of AGE-BSA, and then 30 ng poly(A)RNAs were transcribed
and amplified by PCR at the indicated times. Each lower panel shows expression of -actin genes. PCR amplification for -actin mRNA was
performed for 20 cycles. (B) Quantitative representation of TGF- gene induction by glu-AGE-BSA (), glycer-AGE-BSA (), or methyl-AGE-
BSA ( ). Data were normalized by the intensity of -actin mRNA-derived signals and related to the value of the control with non-glycated BSA.
(C ) Effects of NAC on AGE-induced TGF- mRNA up-regulation. Cells were treated with or without 100 g/mL of various types of AGE-BSA
in the presence or absence of 10 mmol/L of NAC for four hours, and then 30 ng poly(A)RNAs were transcribed and amplified by PCR. Lane
1, control cells treated with non-glycated BSA; lane 2, cells treated with NAC alone; lane 3, cells treated with glu-AGE-BSA and NAC; lane 4,
cells treated with glycer-AGE-BSA and NAC; lane 5, cells treated with methyl-AGE-BSA and NAC. (D) Effects of antibody against glu-AGE-
BSA on TGF- gene expression in tubular cells. Cells were treated with control or diabetic serum in the presence or absence of 10 g/mL of
polyclonal antibody against glu-AGE for four hours, and then poly(A)RNAs were transcribed and amplified by PCR. Lane 1, cells treated with
control serum; lane 2, cells treated with diabetic serum alone; lane 3, cells treated with diabetic serum and antibody. Lower panel shows the
quantitative representation of TGF- gene induction. Data were normalized by the intensity of -actin mRNA-derived signals and related to the
value of the control. Similar results were obtained in two independent experiments.
react with structurally identified AGE-modified BSA, that structurally unidentified immunological epitopes in
the in vitro-modified AGE preparations might exhibitincluding pyrraline-BSA, pentosidine-BSA, argpyrimid-
ine-BSA, 3-deoxyglucosone imidazolone-BSA, carboxy- deleterious effects on proximal tubular cells in diabetes.
That it was AGE-induced intracellular ROS that causedmethyllysine-BSA (CML-BSA), glyoxal-lysine diamer,
or methylglyoxal-lysine dimer [36]. These results suggest de novo protein synthesis inhibition was evidenced as
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nephropathy. Oxidative stress impairs cyclooxygenase-2
activity, suppressing PGE2 secretion by various types of
cells and tissues [41–43], which may provide an explana-
tion of the mechanism for AGE-induced inhibition of
PGE2 secretion by proximal tubular cells.
Evidence has implicated the TGF- system as a major
etiologic agent in the pathogenesis of glomerulosclerosis
and tubulointerstitial fibrosis in diabetic nephropathy
[3, 44, 45]. TGF- stimulates the synthesis of individual
matrix components such as collagen, laminin, and simul-
taneously blocks matrix degradation by increasing con-
centrations of inhibitors of matrix metalloproteinase
[46, 47]. In our study, AGE-induced intracellular ROS
up-regulated the levels of mRNAs for TGF- in proxi-
mal tubular cells. The AGE actually increased the secre-
tion of active TGF- proteins by tubular cells, suggestingFig. 8. Effects of AGE-BSA on active TGF- secretion by tubular
cells. Cells were treated with or without 100 g/mL of various types of the pathological involvements of AGE in the progression
AGE-BSA for 24 hours. Active TGF- released into media was mea- of diabetic nephropathy. The report that latent TGF-sured with an enzyme immunoassay system. *P 	 0.01 compared to
can be activated in vitro upon oxidation with ROS sup-the value of the control with non-glycated BSA (Student t test).
ports our observation [48]. Recently, ROS were reported
to act as signaling molecules in mesangial cells cultured
under high glucose, leading to activation of redox-sensi-
follows. First, AGE-BSA, but not non-glycated BSA, tive transcriptional factors, nuclear factor-B (NF-B)
increased intracellular ROS generation in proximal tubu- and activator factor-1 (AP-1) as well as up-regulation of
lar cells (Fig. 1A). Second, NAC, an intracellular radical TGF- [49]. Therefore, AGE-induced ROS generation
scavenger, completely prevented the inhibitory effects also might stimulate TGF- genes in proximal tubular
of AGE on protein synthesis (Fig. 2A). Third, H2O2 cells through the activation of NF-B and AP-1. We
inhibited de novo protein synthesis in tubular cells in a have just recently found that all of the AGE preparations
dose-dependent manner (Fig. 3). Recently, Ohta et al used in this experiment increased transcriptional activa-
reported that tubular atrophy and interstitial fibrosis are tion of both NF-B and AP-1 promoter in human micro-
cardinal pathologic features of oxidative stress-mediated vascular endothelial cells (unpublished data).
renal injury in patients with heme oxygenase-1 defi- Baynes et al recently demonstrated that AGE inhi-
ciency, supporting our speculation [37]. bitors, including aminoguanidine and OPB-9195, have
In our study, CML-BSA added to the culture medium potent antioxidative, chelating activity in vitro [50]. There-
failed to stimulate ROS generation, and it did not inhibit fore, we cannot entirely exclude the possibility that OPB-
de novo protein synthesis in proximal tubular cells 9195 directly improves renal tubular damage in OLETF
(Figs. 1A and 2A). Since CML adducts of proteins have rats. However, AGE sequestration and the resultant re-
been reported to be ligands for the receptor for AGE, nal elimination by lysozyme recently were found to pro-
tect against renal damage in diabetic rats [51], confirmingtermed RAGE [38], it is probable that AGE receptors
the causal role for AGE in renal abnormalities in diabe-other than RAGE might mediate the AGE effects. In
tes. It is probable that renal improvement associatedour preliminary experiments, RAGE overexpression in
with OPB-9195 administration in OLETF rats is derivedtubular cells did not potentiate the AGE-induced ROS
from inhibitions of AGE formation through its carbonylovergeneration or decrease in de novo protein synthesis,
trapping and chelation activity. The present observationssupporting our speculation (data not shown).
suggest the active participation of AGE in tubular injuryThe present study also demonstrates that AGE inhib-
in diabetes, thus providing a basis for understandingited PGE2 secretion by proximal tubular cells through
the favorable molecular events in OLETF rats givenintracellular ROS generation. PGE2 is a vasodilator and
OPB-9195.angiogenic prostanoid that can regulate blood supply to
proximal tubules [39]. Since chronic tubulointerstitial
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